A case of primary squamous cell carcinoma of the breast with pathologic complete response after neoadjuvant chemotherapy

Alan, Özkan; Telli, Tuğba Akın; Ercelep, Özlem; Hasanov, Rahib; Şimşek, Eda Tanrikulu; Mutis, Aydan; Öneş, Tunç; Kaya, Hakan; Yumuk, Perran Fulden

doi:10.1016/j.currproblcancer.2018.04.003

Cited by 12 publications

(11 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to its low incidence, the diagnosis, treatment, and evaluation of BSqCC were quite tricky. There was no standard treatment plan ( 10 , 13 ), and surgery-based comprehensive treatment was usually used. Our study showed that the surgical procedure was an independent risk factor for patient survival, with statistically significant differences (P<0.001).…”

Section: Discussionmentioning

confidence: 99%

“…This has made it challenging to study epidemiological characteristics. Most epidemiological studies are limited by the rare cases, except for the report of Yadav et al (8) with a large amount of data, most studies are limited to reports in a single case (9)(10)(11)(12). The surveillance, epidemiology, and end results (SEER) database brings together data from multiple medical centers in the United States, providing a sufficient sample size of rare cancers for epidemiological studies.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic factors for breast cancer squamous cell carcinoma and nomogram development for prediction: population-based research

Cheng¹,

Han²,

Zhang³

et al. 2019

Transl. Cancer Res.

View full text Add to dashboard Cite

Background: To investigate the prognostic survival factors of breast squamous cell carcinoma (BSqCC) and develop a comprehensive nomogram for predicting the survival of breast cancer squamous cell carcinoma. Methods: Data were obtained from the Surveillance, Epidemiology, and End Results (SEER) database to identify patients diagnosed with BSqCC from 1973 to 2015. The data was obtained using SEER Stat 8.3.4 software, collated, and analyzed by Excel 2016 software and SPSS (v25.0). Kaplan-Meier curves were used for survival analysis. The variables obtained by univariate analysis were introduced into the Cox proportional hazard model for multivariate analysis. The risk factors affecting the prognosis of BSqCC were obtained. P<0.05 was considered statistically significant. The independent prognostic factors of BSqCC were integrated and used to construct nomograms.Results: A total of 739 patients with BSqCC was included. The median age of diagnosis was 66 years. In most cases, the expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) was negative. One-third of the cases underwent breast-conserving surgery, and more than half of the cases underwent mastectomy (unilateral or bilateral). The 1-year survival rate was 81.2%, the 3-year survival rate was 62.9%, the 5-year survival rate was 54.4%, and the 10-year survival rate was 41.4%. Age (χ 2 =71.050, P<0.001), marital status (χ 2 =37.560, P<0.001), tumor size (χ 2 =27.931, P<0.001), surgical procedure (χ 2 =74.185, P<0.001), the number of positive lymph nodes (χ 2 =38.542, P<0.001), and the primary site (χ 2 =59.217, P<0.001) were significantly correlated with patient survival time. Among them,

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Prognostic factors for breast cancer squamous cell carcinoma and nomogram development for prediction: population-based research

Cheng¹,

Han²,

Zhang³

et al. 2019

Transl. Cancer Res.

View full text Add to dashboard Cite

show abstract

“…Details are shown in Table 1. Alan et al (25) reported a case of pathologic complete tumor response using TAC (Paclitaxel, epirubicin, and cyclophosphamide) as neoadjuvant chemotherapy. However, some scholars have pointed out that cyclophosphamide, fluorouracil, and anthracyclines are not sensitive to breast squamous cell carcinoma (24).…”

Section: Discussionmentioning

confidence: 99%

Significant efficacy of paclitaxel plus carboplatin (TP) as a neoadjuvant regimen for metaplastic squamous cell carcinoma of the breast: a rare case report and literature review

Chen¹,

Jiang²,

Luo³

et al. 2022

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background: Metaplastic squamous cell carcinoma of the breast (MSCCB) is a rare and aggressive type of cancer. So far, no standard treatment regimen has been established due to the absence of clinical data.Case Description: We report a case of a 48-year-old female admitted to our hospital as a result of a left breast mass with skin rupture. Core needle biopsy under ultrasonic guidance confirmed MSCCB.Immunohistochemistry revealed negative staining for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor type 2 (HER2/neu). After receiving 4 cycles of paclitaxel and carboplatin neoadjuvant chemotherapy, the patient was treated with modified radical mastectomy.Postoperative pathology revealed a Miller-Payne score of 4 and no metastasis in the axillary lymph nodes (0/13), indicating a good response to neoadjuvant chemotherapy. She recovered well post-surgery and was discharged to home after admission. No recurrence was identified during the 2 years post-surgery follow-up.Conclusions: MSCCB is a rare and aggressive type of cancer. However, the treatment of MSCCB has not been standardized due to its rarity. Given the observation that the majority of patients with MSCCB had ER, PR, HER2-negative neoplasms, we refer to the triple negative breast cancer (TNBC) treatment protocol.TP regimen was demonstrated to be an effective treatment for TNBC. The results of this case suggest that the TP regimen is effective in neoadjuvant chemotherapy of MSCCB.

show abstract

“…Alan et al [ 20 ] showed a unique case of a patient with a triple-negative SCC tumor of 6.5 cm in diameter that showed complete pathological response after NAC with weekly paclitaxel followed by treatment with the combination of epirubicin and cyclophosphamide. This case was comparable to our case.…”

Section: Discussionmentioning

confidence: 99%

A Case of Metaplastic Squamous Cell Carcinoma of the Breast that Showed a Pathological Complete Response After Neoadjuvant Chemotherapy with Weekly Paclitaxel

Noro

Ishitobi

Hanamura³

et al. 2021

Am J Case Rep

View full text Add to dashboard Cite

Patient: Female, 40-year-old Final Diagnosis: Squamous cell carcinoma of the breast Symptoms: A palpable tumor of the right breast Medication: — Clinical Procedure: Core needle biopsy Specialty: Oncology Objective: Unusual or unexpected effect of treatment Background: Primary squamous cell carcinoma of the breast is a rare type of metaplastic breast carcinoma, characterized by resistance to conventional chemotherapy agents. We report a case of metaplastic squamous cell carcinoma of the breast in which a pathological complete response was achieved after neoadjuvant chemotherapy with weekly paclitaxel and in which the patient remained disease free for 15 years and 7 months. Case Report: A 40-year-old woman had a palpable 5-cm-diameter tumor in the right breast that was diagnosed as meta-plastic squamous cell carcinoma of the breast based on core needle biopsy. The patient was initially treated with an adjuvant chemotherapy (AC) regimen consisting of doxorubicin (60 mg/m 2 ) and cyclophosphamide (600 mg/m 2 ) as neoadjuvant chemotherapy. Because the tumor grew rapidly and the skin redness increased after 1 cycle of the AC regimen, 12 cycles of weekly paclitaxel 80 mg/m 2 were subsequently administered. The tumor responded dramatically to paclitaxel. The patient underwent mastectomy with level II axillary lymph node dissection. No residual tumor cells were found, which indicated pathological complete response. The patient is currently disease free at 15 years and 7 months after the operation. Conclusions: To our knowledge, there are no previous reports of metaplastic squamous cell carcinoma of the breast in which pathological complete response was achieved by treatment with neoadjuvant chemotherapy with weekly paclitaxel (80 mg/m 2 ).

show abstract

A case of primary squamous cell carcinoma of the breast with pathologic complete response after neoadjuvant chemotherapy

Cited by 12 publications

References 7 publications

Prognostic factors for breast cancer squamous cell carcinoma and nomogram development for prediction: population-based research

Prognostic factors for breast cancer squamous cell carcinoma and nomogram development for prediction: population-based research

Significant efficacy of paclitaxel plus carboplatin (TP) as a neoadjuvant regimen for metaplastic squamous cell carcinoma of the breast: a rare case report and literature review

A Case of Metaplastic Squamous Cell Carcinoma of the Breast that Showed a Pathological Complete Response After Neoadjuvant Chemotherapy with Weekly Paclitaxel

Contact Info

Product

Resources

About